



# Supplemental Figure 1



Mock

Day 4 Post Infection



Brain





Kidney



Liver




Spleen





# Supplemental Figure 3



1 **Supplemental Figure 1: Characterization of SARS-CoV-2 disease pathogenesis.** Representative images of  
2 brain, kidney, liver, and spleen tissue from moribund K18-hACE2 mice on day 4 post-infection relative to  
3 uninfected controls. Images are shown at 400X magnification (Black bar = 20  $\mu$ m). Images are  
4 representative of 2 separate experiments with n= 10 mice per group.

5

6 **Supplemental Figure 2: SARS-CoV-2 infection drives dysregulation in multiple pathways including amino**  
7 **acid and hypoxanthine metabolism.** Semi-targeted analysis of soluble metabolites in the lungs of SARS-  
8 CoV-2 infected K18-hACE2 mice over time. Data is shown as the mean of the  $\log_2$  Fold Change values  
9 relative to the mock control (N=5 mice), and whether the corresponding False Discovery Rate was greater  
10 or less than 10%.

11

12 **Supplemental Figure 3: Flow Cytometry Gating strategy.** Representative gating scheme from a day 4 lung  
13 sample. After gating on CD45<sup>+</sup> cells, Zombie<sup>-</sup> and Zombie<sup>+</sup> populations were identified. Subsequent gates  
14 for individual myeloid populations are shown for the Zombie<sup>-</sup> gate to demonstrate how gates were drawn.  
15 The Boolean logic tool “Not Gate” within FlowJo was used as indicated by the arrows. The same gates  
16 were copied onto the Zombie<sup>+</sup> population. Only the Zombie<sup>-</sup> populations are shown due to the number of  
17 events within all gates.

18



**Supplemental Table 1: Cytokine/Chemokine Array on Lungs from uninfected and SARS-CoV-2 infected mice treated with or without FPS-ZM1**

	Vehicle			FPS-ZM1		
	Uninfected	Day 2 post infection	Day 4 post infection	Uninfected	Day 2 post infection	Day 4 post infection
<b>TH-1 Pro-inflammatory Cytokines</b>						
<b>TNF-<math>\alpha</math></b>	2.71 $\pm$ 0.13	7.58 $\pm$ 0.74	53.28 $\pm$ 3.67***	1.74 $\pm$ 0.11	13.49 $\pm$ 3.49	33.10 $\pm$ 2.68***bbb
<b>IL-6</b>	21.67 $\pm$ 2.21	33.13 $\pm$ 2.01	132.90 $\pm$ 7.95***	18.70 $\pm$ 1.03	41.65 $\pm$ 8.27	91.14 $\pm$ 13.19***bb
<b>IL-5</b>	0.20 $\pm$ 0.09	7.92 $\pm$ 1.01	73.11 $\pm$ 7.74***	0.67 $\pm$ 0.23	15.71 $\pm$ 4.60	47.59 $\pm$ 6.67***bb
<b>IL-2</b>	83.57 $\pm$ 7.86	127.83 $\pm$ 9.25	534.54 $\pm$ 52.01***	82.95 $\pm$ 6.80	145.96 $\pm$ 25.91	405.47 $\pm$ 38.62***b
<b>IL-1<math>\beta</math></b>	0.14 $\pm$ 0.09	0.39 $\pm$ 0.07	1.24 $\pm$ 0.11***	0.17 $\pm$ 0.03	0.27 $\pm$ 0.05	0.94 $\pm$ 0.08***b
<b>IL-12p70</b>	B.D	0.39 $\pm$ 0.21	4.70 $\pm$ 0.70***	B.D	1.55 $\pm$ 0.39 <sup>a</sup>	4.36 $\pm$ 0.90***
<b>IFN-<math>\gamma</math></b>	0.11 $\pm$ 0.03	2.12 $\pm$ 0.44	17.49 $\pm$ 2.03***	0.05 $\pm$ 0.02	4.67 $\pm$ 1.74	10.12 $\pm$ 1.05***bbb
<b>IFN-<math>\alpha</math></b>	10644.85 $\pm$ 495.13	8535.31 $\pm$ 958.08	9646.37 $\pm$ 1827.23	9830.68 $\pm$ 291.29	6602.54 $\pm$ 1383.98	5322.86 $\pm$ 470.30 <sup>b</sup>
<b>IFN-<math>\beta</math></b>	6.16 $\pm$ 0.31	8.93 $\pm$ 0.82	24.73 $\pm$ 1.33***	4.79 $\pm$ 0.46	13.06 $\pm$ 2.60*	19.43 $\pm$ 1.03***b
<b>IL-12p40</b>	254.74 $\pm$ 8.80	475.70 $\pm$ 35.31	1914.12 $\pm$ 170.01***	232.55 $\pm$ 24.47	507.04 $\pm$ 65.55	1286.94 $\pm$ 70.78***bbb
<b>IL-17A</b>	13.08 $\pm$ 1.14	14.58 $\pm$ 2.01	18.71 $\pm$ 2.33	9.71 $\pm$ 0.85	14.68 $\pm$ 1.93	18.69 $\pm$ 1.75
<b>IL-17C</b>	15.56 $\pm$ 1.06	20.29 $\pm$ 3.24	43.82 $\pm$ 7.11	30.11 $\pm$ 16.33	21.28 $\pm$ 3.14	46.74 $\pm$ 10.80
<b>IL-17E</b>	15.65 $\pm$ 1.14	13.21 $\pm$ 1.65	14.22 $\pm$ 1.15	7.35 $\pm$ 0.92	10.97 $\pm$ 1.14	17.46 $\pm$ 1.06
<b>IL-17A/F</b>	0.66 $\pm$ 0.10	1.74 $\pm$ 0.32	7.26 $\pm$ 0.39***	0.42 $\pm$ 0.08	2.15 $\pm$ 0.63	4.19 $\pm$ 0.62***bbb
<b>CD40</b>	319.59 $\pm$ 11.34	360.04 $\pm$ 45.28	2130.99 $\pm$ 217.13***	288.05 $\pm$ 31.89	376.40 $\pm$ 56.78	940.08 $\pm$ 128.08 <sup>bbb</sup>
<b>IL-16</b>	17774.59 $\pm$ 608.30	14731.87 $\pm$ 491.58*	15044.16 $\pm$ 402.96*	16992.54 $\pm$ 715.31	13106.20 $\pm$ 832.84***	13974.31 $\pm$ 713.83**
<b>MMP-9</b>	10413.49 $\pm$ 833.93	15550.17 $\pm$ 1431.35*	5742.51 $\pm$ 1295.23	7019.63 $\pm$ 1159.83	9166.49 $\pm$ 1565.63 <sup>aa</sup>	4945.51 $\pm$ 357.08*
<b>TNF-R1</b>	175.06 $\pm$ 32.93	238.63 $\pm$ 33.24	414.03 $\pm$ 52.90**	108.33 $\pm$ 19.41	201.20 $\pm$ 49.95	288.89 $\pm$ 25.52 <sup>b</sup>
<b>NGAL</b>	192920.60 $\pm$ 15342.63	268320.50 $\pm$ 39674.54	249663.50 $\pm$ 47605.87	721420.50 $\pm$ 394803.19	278367.80 $\pm$ 28676.95	106973.80 $\pm$ 20375.09 <sup>b</sup>

**Chemokines**

<b>MCP-5</b>	15.65±0.62	94.42±9.78*	305.32±21.24***	13.47±0.39	102.64±18.07*	188.19±13.13***b
<b>MDC</b>	402.40±7.73	598.18±54.49*	503.28±36.56	290.35±27.57	555.00±59.77	470.02±20.43
<b>BCA-1</b>	2296.18±102.93	2355.22±151.59	2997.14±194.88*	2312.61±126.01	2204.99±201.61	2266.91±82.77 <sup>bb</sup>
<b>IP-10</b>	88.03±4.93	3062.19±412.51**	12578.56±812.67***	74.01±74.01	5855.37±5855.37	7076.24±7076.24*** <sup>bbb</sup>
<b>KC</b>	0.24±0.24	0.82±0.82	2.14±2.14***	0.30±0.30	0.82±0.82	1.67±1.67***
<b>MCP-1</b>	12.95±1.12	88.56±15.07	945.24±78.74***	12.03±0.50	181.47±57.40	516.03±79.26*** <sup>bbb</sup>
<b>MIP-1α</b>	15.89±3.32	51.66±8.30	267.64±24.6***	11.04±1.65	79.87±22.59	210.60±21.83***
<b>MIP-1β</b>	51.00±5.35	146.87±24.30	527.84±38.51***	38.54±5.06	220.65±52.16*	410.06±46.02***
<b>MIP-2</b>	6.38±0.64	11.10±1.00	29.40±1.25***	5.28±0.30	12.97±2.46*	23.43±1.26*** <sup>b</sup>
<b>MIP-3α</b>	11.70±0.83	19.82±3.32	68.88±9.32***	10.32±1.39	19.17±3.69	40.55±7.70 <sup>bb</sup>
<b>Eotaxin</b>	106558.40±7063.18	99877.50±7408.43	135373.40±8793.24	95990.00±3951.17	96833.00±9621.77	106184.30±6467.64 <sup>b</sup>
<b>RANTES</b>	1263.75±240.27	708.30±61.31*	860.52±188.97	588.86±131.77*	567.38±117.95**	544.85±44.79*** <sup>bb</sup>
<b>SDF-1α</b>	23.50±3.53	53.47±7.98	124.38±17.43***	21.60±7.74	65.30±16.72	85.86±13.16*
<b>TARC</b>	137.58±12.69	127.65±10.17	118.79±16.79	109.56±0.74	91.87±15.97	97.00±12.27
<b>6CKine</b>	305.27±7.56	330.99±10.10	1010.71±103.32	353.27±27.47	371.06±10.19	692.35±89.56 <sup>bb</sup>
<b>TH2/Regulatory Cytokines</b>						
<b>IL-21</b>	949.29±46.74	1,102.24±120.14	1,455.73±189.17	712.38±44.53	1,102.51±118.68	1,432.13±136.16
<b>IL-22</b>	5.57±0.40	9.15±1.46	20.56±2.49***	4.88±0.22	10.54±1.91	15.54±1.08**
<b>IL-9</b>	10.70±0.88	28.89±3.18	116.88±6.24***	8.05±0.81	34.49±7.96	77.46±6.53*** <sup>bbb</sup>
<b>IL-10</b>	1.70±1.05	3.34±0.50	4.51±3.67	3.05±0.29	3.71±0.98	4.60±1.02
<b>IL-13</b>	0.01±0.01	0.08±0.05	0.50±0.40*	0.01±0.01	0.04±0.02	0.67±0.13**
<b>IL-4</b>	26.08±26.08	53.57±10.59	166.80±133.54	7.86±6.50	121.67±14.69 <sup>aa</sup>	215.03±55.55**
<b>IL-15</b>	121.80±74.59	703.03±88.63	1,975.27±746.58***	409.78±161.26	886.37±157.06	1,782.20±506.48***

<b>IL-17F</b>	570.04±81.63	388.43±52.76	517.83±333.04	299.63±61.04	434.54±97.83	843.75±64.90
<b>IL-23</b>	2.82±0.39	2.06±0.33	2.47±1.24	1.26±0.12	2.23±0.26	3.06±0.34
<b>IL-27p28</b>	270.95±201.06	482.49±138.53	1,385.71±874.80	647.92±263.76	1,259.99±251.67 <sup>a</sup>	1,303.05±640.17
<b>IL-31</b>	463.202±211.85	339.23±133.99	3,063.87±955.29***	467.372±209.84	1,873.42±292.31* <sup>aa</sup>	1,967.68±604.11*
<b>IL-33</b>	252.46±112.86	300.80±50.10	699.11±444.92	255.12±73.59	200.89±58.97	962.79±186.08**

**Growth Factors/Hormones**

<b>GM-CSF</b>	1.06±0.07	1.44±0.08	4.10±0.20***	1.01±0.05	1.43±0.18	2.87±0.19*** <sup>bbb</sup>
<b>VEGF</b>	79.28±44.64	101.27±30.56	316.64±94.83**	39.40±13.42	119.74±22.89	280.07±11.30**
<b>Erythropoietin</b>	B.D	0.02±0.02	1.43±0.49**	B.D	B.D	0.36±0.24 <sup>b</sup>
<b>BAFF</b>	7718.83±133.49	9457.37±351.86	11503.07±299.39	9998.84±261.39 <sup>a</sup>	9899.54±522.93	11304.99±1059.52

---

Data are shown as mean concentration (pg/mL) ± SEM (n=5-10 mice per group pooled from 2 experiments) for all cytokines except BAFF, NGAL, and 6CKine (n=4 per group). B.D. indicates below the detection limit of the assay. \*p<0.05, \*\*p<0.01, \*\*\*p<0.001 indicates significance change in cytokine/chemokine level over time relative to uninfected and vehicle treated control. <sup>a</sup>p<0.05, <sup>aa</sup>p<0.01, <sup>aaa</sup>p<0.001 indicates significance between vehicle and FPS treatment in SARS-CoV-2 infected mice on day 2 post infection. <sup>b</sup>p<0.05, <sup>bb</sup>p<0.01, <sup>bbb</sup>p<0.001 indicates significance between vehicle and FPS treatment of SARS-CoV-2 infected mice on Day 4 post infection. Comparisons between groups were assessed using a 2-way ANOVA with Dunnett's post test.

---